Approximately 60% of patients with diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, can be cured with anti-CD20 antibody in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) [1]. This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.